For Brain Health
We are developing diagnosis of prodromal dementia and therapeutics for Alzheimer’s Disease and dementia with Lewy bodies.
About Us
BRI Pharma evaluates risk of dementia with blood and supplies the preventive tools of dementia.
Technologies
BRI Pharma develops disease-modifying drugs for AD and DLB.
Partnering
BRI Pharma is engaged with health science companies and collaborates with CNS targeting companies.
R&D Portfolio
Novel drug candidates for AD and DLB and Diagnosis Technologies.
BRI-301: T-type calcium channel enhancer
BRI-101: FABP3 inhibitor
BRI-601: FABP7 inhibitor
B-refine: diagnostic system
Latest News
Click here for the article
Click here for the article.
Click here for the article.
